RLAY Relay Therapeutics, Inc. Stock Quote

RLAY [NASD]

Index	-	P/E	-	EPS (ttm)	-2.59	Insider Own	0.50%	Shs Outstand	108.64M	Perf Week	15.54%
Market Cap	2.75B	Forward P/E	-	EPS next Y	-3.10	Insider Trans	-28.05%	Shs Float	106.14M	Perf Month	27.58%
Income	-267.10M	PEG	-	EPS next Q	-0.71	Inst Own	-	Short Float	17.35%	Perf Quarter	56.29%
Sales	2.00M	P/S	1373.08	EPS this Y	-49.40%	Inst Trans	7.32%	Short Ratio	17.06	Perf Half Y	12.67%
Book/sh	7.18	P/B	3.53	EPS next Y	-13.50%	ROA	-30.40%	Target Price	39.00	Perf Year	-25.07%
Cash/sh	7.74	P/C	3.28	EPS next 5Y	-	ROE	-34.60%	52W Range	12.65 - 38.15	Perf YTD	-17.45%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-40.60%	52W High	-20.09%	Beta	-
Dividend %	-	Quick Ratio	19.50	Sales past 5Y	-	Gross Margin	-	52W Low	140.99%	ATR	2.09
Employees	305	Current Ratio	19.50	Sales Q/Q	-50.00%	Oper. Margin	-	RSI (14)	69.61	Volatility	10.08% 9.64%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	66.40%	Profit Margin	-	Rel Volume	13.22	Prev Close	25.35
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 04 AMC	Payout	-	Avg Volume	1.08M	Price	30.49
Recom	2.10	SMA20	36.16%	SMA50	46.67%	SMA200	29.77%	Volume	2,208,081	Change	20.26%

Sep-02-22

Initiated

Stifel

Buy

$40

Jun-06-22

Initiated

Jefferies

Underperform

$13

Feb-01-22

Initiated

Berenberg

Buy

$45

Jul-21-21

Initiated

BofA Securities

Buy

$50

Dec-15-20

Reiterated

H.C. Wainwright

Buy

$54 → $57

Dec-08-20

Initiated

JMP Securities

Mkt Outperform

$66

Nov-05-20

Initiated

H.C. Wainwright

Buy

$54

Aug-10-20

Initiated

JP Morgan

Neutral

$36

Aug-10-20

Initiated

Guggenheim

Buy

$48

Aug-10-20

Initiated

Goldman

Buy

$64

Aug-10-20

Initiated

Cowen

Outperform

Aug-30-22 11:15AM	For This AI Drug Developer, Look Beyond the Rally TheStreet.com -5.43%
Aug-25-22 02:48PM	Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating Investor's Business Daily
Aug-18-22 04:05PM	Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress GlobeNewswire
Aug-04-22 04:05PM	Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Jul-28-22 04:05PM	Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire -5.73%
Jun-27-22 06:00AM	Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event GlobeNewswire -10.54%
Jun-16-22 07:30AM	Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event GlobeNewswire
May-26-22 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
May-07-22 09:59AM	Relay Therapeutics (NASDAQ:RLAY shareholders incur further losses as stock declines 13% this week, taking one-year losses to 30% Simply Wall St.
May-05-22 04:05PM	Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire -9.06%
May-03-22 07:30AM	Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference GlobeNewswire
Apr-28-22 04:05PM	Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Feb-24-22 04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights GlobeNewswire +5.91%
Feb-17-22 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights GlobeNewswire
Feb-10-22 11:51AM	Bargain Shopping? 3 Strong Buy Stocks That Are Down Over 50% TipRanks -5.91%
Feb-02-22 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire -5.07%
Jan-04-22 07:30AM	Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008 GlobeNewswire
Jan-03-22 07:30AM	Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.37%
Dec-22-21 11:11AM	Biotech: Interest in vaccine stocks will probably wane, strategist says Yahoo Finance Video
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-10-21 07:30AM	Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination GlobeNewswire
Nov-17-21 11:39AM	Notable Relay Therapeutics Insider Trades $890K In Company Stock Benzinga
Nov-16-21 12:36PM	How Many Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Do Institutions Own? Simply Wall St.
Nov-10-21 04:05PM	Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
Nov-04-21 04:05PM	Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
08:14AM	Section 32 Raises $740 Million Venture Fund PR Newswire
Oct-27-21 01:23PM	J.P. Morgan Sees These 3 Strong Buy Stocks Climbing Over 50% TipRanks
04:50AM	10 Pharma Stocks to Buy According to Mark Lamperts Biotechnology Value Fund Insider Monkey
Oct-15-21 09:01AM	Why Relay Therapeutics Is Up 30% This Week Motley Fool -6.85%
Oct-12-21 09:58PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -5.22%
04:27AM	5 Stocks To Watch For October 12, 2021 Benzinga
Oct-11-21 04:15PM	Relay Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-08-21 12:24PM	Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial Benzinga +8.31%
06:00AM	Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor GlobeNewswire
Oct-07-21 08:50AM	Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3K GlobeNewswire -11.86%
Sep-13-21 06:00AM	Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference GlobeNewswire +11.04%
Aug-18-21 10:27AM	Time To Worry? Analysts Are Downgrading Their Relay Therapeutics, Inc. (NASDAQ:RLAY) Outlook Simply Wall St.
Aug-15-21 04:06AM	Relay Therapeutics, Inc. (NASDAQ:RLAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
Aug-12-21 04:05PM	Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-05-21 04:05PM	Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
Jul-20-21 10:48PM	Is Relay Therapeutics, Inc. (RLAY) A Good Stock To Buy? Insider Monkey
Jul-19-21 09:26AM	Relay Therapeutics (NASDAQ:RLAY) Share Prices Have Dropped 24% In The Last Year Simply Wall St.
Jun-02-21 06:00AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
May-14-21 06:00AM	Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit GlobeNewswire +6.15%
May-13-21 04:05PM	Relay Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire
May-10-21 06:00AM	Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D. GlobeNewswire -6.07%
May-05-21 06:00AM	Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference GlobeNewswire
May-03-21 06:00AM	Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara OMeara and Charles Ferté GlobeNewswire
Apr-16-21 11:31AM	Relay Therapeutics Inks $85M Deal To Buy ZebiAI SmarterAnalyst
06:00AM	Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI GlobeNewswire
Apr-14-21 05:57AM	Are Insiders Buying Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock? Simply Wall St. +6.51%
Mar-25-21 04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights GlobeNewswire
Mar-10-21 04:30PM	Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting GlobeNewswire +6.18%
Feb-04-21 04:05PM	Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day GlobeNewswire
Jan-14-21 04:26AM	We Think Relay Therapeutics (NASDAQ:RLAY) Can Easily Afford To Drive Business Growth Simply Wall St.
Jan-06-21 05:00PM	SoftBanks Son Is Poised for Another IPO Windfall in 2021 Bloomberg
06:00AM	Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-20 10:36PM	Is RLAY A Good Stock To Buy Now? Insider Monkey
Dec-14-20 06:00AM	Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971 GlobeNewswire -12.47%
Nov-12-20 04:05PM	Relay Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire
Oct-16-20 10:53AM	Are Insiders Buying Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock? Simply Wall St. +8.13%
Sep-03-20 04:05PM	Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor GlobeNewswire
Aug-27-20 06:50AM	Relay Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-16-20 08:59AM	Goldman Sachs: These 3 Stocks Can Deliver Big Returns for Investors TipRanks
Aug-11-20 06:40AM	SoftBank Moves Into Asset Management After Return to Profits Bloomberg
Aug-06-20 06:07PM	Sons SoftBank Poised to Return to Profit After Big Losses Bloomberg +8.40%
Jul-20-20 04:05PM	Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-17-20 04:17PM	Berkeley Lights IPO Jumps By Triple Digits As Hot Biotech Begins Trading Investor's Business Daily +25.48%
Jul-16-20 04:28PM	Relay Therapeutics IPO Raises $400 Million As Stock Soars Investor's Business Daily
01:25PM	Word on the street: These two IPOs might be worth investing in Yahoo Finance Video
12:02PM	Relay Therapeutics's stock sprints out of the gate, after upsized IPO priced above recently raised expectations MarketWatch
Jul-15-20 08:51PM	Relay Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
07:34AM	Relay Therapeutics upsizes and raises proposed price range for IPO MarketWatch

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bergstrom Donald A	President, R&D	Sep 02	Option Exercise	4.12	4,900	20,188	94,559	Sep 02 05:47 PM
Bergstrom Donald A	President, R&D	Sep 02	Sale	25.46	4,900	124,754	89,659	Sep 02 05:47 PM
Bergstrom Donald A	President, R&D	Sep 01	Option Exercise	4.12	8,100	33,372	97,759	Sep 01 08:26 PM
Bergstrom Donald A	President, R&D	Sep 01	Sale	23.07	8,100	186,867	89,659	Sep 01 08:26 PM
Bergstrom Donald A	President, R&D	Aug 24	Option Exercise	4.12	15,000	61,800	104,659	Aug 25 05:23 PM
Bergstrom Donald A	President, R&D	Aug 24	Sale	25.00	15,000	375,000	89,659	Aug 25 05:23 PM
Bergstrom Donald A	President, R&D	Aug 05	Option Exercise	4.12	8,000	32,960	97,659	Aug 08 05:38 PM
Bergstrom Donald A	President, R&D	Aug 05	Sale	20.00	8,000	160,000	89,659	Aug 08 05:38 PM
Porter Andy	Chief Administrative Officer	Jul 28	Sale	21.27	452	9,614	45,871	Jul 29 04:57 PM
Catinazzo Thomas	Chief Financial Officer	Jul 28	Sale	21.26	734	15,605	52,218	Jul 29 04:53 PM
Bergstrom Donald A	President, R&D	Jul 28	Sale	21.27	1,835	39,030	89,659	Jul 29 04:45 PM
Adams Brian	Chief Legal Officer	Jul 28	Sale	21.27	734	15,612	62,842	Jul 29 04:42 PM
Bergstrom Donald A	President, R&D	Jul 06	Option Exercise	4.12	8,000	32,960	99,494	Jul 08 04:17 PM
Bergstrom Donald A	President, R&D	Jul 06	Sale	20.00	8,000	160,000	91,494	Jul 08 04:17 PM
Porter Andy	Chief Administrative Officer	Jun 27	Sale	20.31	265	5,382	46,323	Jun 28 06:03 PM
Catinazzo Thomas	Chief Financial Officer	Jun 27	Sale	20.31	300	6,093	52,952	Jun 28 05:59 PM
Adams Brian	Chief Legal Officer	Jun 27	Sale	20.31	300	6,093	63,576	Jun 28 05:56 PM
Bergstrom Donald A	President, R&D	Jun 27	Sale	20.31	999	20,290	91,494	Jun 28 05:53 PM
Bergstrom Donald A	President, R&D	Jun 24	Option Exercise	4.12	8,000	32,960	100,493	Jun 28 05:53 PM
Bergstrom Donald A	President, R&D	Jun 24	Sale	20.00	8,000	160,000	92,493	Jun 28 05:53 PM
Bergstrom Donald A	President, R&D	May 02	Option Exercise	4.12	13,000	53,560	105,493	May 02 08:24 PM
Bergstrom Donald A	President, R&D	May 02	Sale	24.62	13,000	320,060	92,493	May 02 08:24 PM
Bergstrom Donald A	President, R&D	Apr 28	Sale	25.57	1,811	46,307	92,493	May 02 08:24 PM
Porter Andy	Chief Administrative Officer	Apr 28	Sale	25.57	435	11,123	46,588	May 02 08:13 PM
Catinazzo Thomas	Chief Financial Officer	Apr 28	Sale	25.57	725	18,538	53,252	May 02 08:07 PM
Adams Brian	Chief Legal Officer	Apr 28	Sale	25.57	708	18,104	63,876	May 02 08:03 PM
Patel Sanjiv	President and CEO	Apr 14	Option Exercise	4.58	28,000	128,240	267,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 14	Sale	30.51	28,000	854,280	253,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 13	Option Exercise	4.58	28,000	128,240	267,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 13	Sale	31.95	28,000	894,600	253,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 12	Option Exercise	4.12	28,000	115,360	281,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 12	Sale	31.80	28,000	890,400	253,740	Apr 14 09:20 PM
Bergstrom Donald A	President, R&D	Apr 01	Option Exercise	4.12	18,000	74,160	112,304	Apr 05 05:32 PM
Bergstrom Donald A	President, R&D	Apr 01	Sale	30.32	18,000	545,760	94,304	Apr 05 05:32 PM
Porter Andy	Chief Administrative Officer	Mar 29	Sale	29.87	294	8,782	47,023	Mar 31 05:49 PM
Catinazzo Thomas	Chief Financial Officer	Mar 29	Sale	29.87	282	8,423	53,977	Mar 31 05:45 PM
Adams Brian	Chief Legal Officer	Mar 29	Sale	29.87	333	9,947	64,584	Mar 31 05:37 PM
Bergstrom Donald A	President, R&D	Mar 29	Sale	29.87	622	18,579	94,304	Mar 31 05:41 PM
Bergstrom Donald A	President, R&D	Mar 24	Option Exercise	4.12	10,000	41,200	104,926	Mar 28 08:11 PM
Catinazzo Thomas	Chief Financial Officer	Mar 24	Option Exercise	4.12	13,286	54,738	67,545	Mar 28 08:18 PM
Catinazzo Thomas	Chief Financial Officer	Mar 24	Sale	30.00	13,286	398,580	54,259	Mar 28 08:18 PM
Bergstrom Donald A	President, R&D	Mar 24	Sale	30.00	10,000	300,000	94,926	Mar 28 08:11 PM
Bergstrom Donald A	President, R&D	Mar 10	Option Exercise	4.12	10,000	41,200	104,926	Mar 11 07:02 PM
Bergstrom Donald A	President, R&D	Mar 10	Sale	25.00	10,000	250,000	94,926	Mar 11 07:02 PM
Bergstrom Donald A	President, R&D	Mar 01	Option Exercise	4.12	8,000	32,960	102,926	Mar 03 05:31 PM
Bergstrom Donald A	President, R&D	Mar 01	Sale	23.88	8,000	191,040	94,926	Mar 03 05:31 PM
Bergstrom Donald A	President, R&D	Feb 22	Option Exercise	4.12	8,000	32,960	117,920	Feb 22 09:01 PM
Bergstrom Donald A	President, R&D	Feb 22	Sale	20.94	22,994	481,577	94,926	Feb 22 09:01 PM
Catinazzo Thomas	Senior Vice President, Finance	Dec 27	Sale	33.10	295	9,764	14,989	Dec 27 07:43 PM
Porter Andy	See Remarks	Dec 27	Sale	33.10	260	8,606	23,147	Dec 27 07:50 PM
Bergstrom Donald A	See Remarks	Dec 27	Sale	33.10	649	21,482	44,970	Dec 27 07:39 PM
Adams Brian	General Counsel	Dec 27	Sale	33.10	295	9,764	24,989	Dec 27 07:31 PM
Catinazzo Thomas	Senior Vice President, Finance	Nov 15	Option Exercise	4.12	22,500	92,700	37,784	Nov 16 07:14 PM
Adams Brian	General Counsel	Nov 15	Option Exercise	4.12	6,500	26,780	31,784	Nov 16 07:07 PM
Adams Brian	General Counsel	Nov 15	Sale	35.42	6,500	230,230	25,284	Nov 16 07:07 PM
Catinazzo Thomas	Senior Vice President, Finance	Nov 15	Sale	35.40	22,500	796,500	15,284	Nov 16 07:14 PM
Bergstrom Donald A	See Remarks	Oct 15	Sale	34.15	30,000	1,024,500	45,619	Oct 19 08:56 PM
Catinazzo Thomas	Senior Vice President, Finance	Sep 27	Sale	36.87	293	10,803	15,284	Sep 27 09:33 PM
Bergstrom Donald A	See Remarks	Sep 27	Sale	36.87	646	23,818	75,619	Sep 27 09:27 PM
Adams Brian	General Counsel	Sep 27	Sale	36.87	293	10,803	25,284	Sep 27 09:21 PM
Catinazzo Thomas	Senior Vice President, Finance	Sep 13	Option Exercise	4.12	22,500	92,700	38,077	Sep 13 08:24 PM
Adams Brian	General Counsel	Sep 13	Option Exercise	4.12	6,500	26,780	32,077	Sep 13 08:27 PM
Catinazzo Thomas	Senior Vice President, Finance	Sep 13	Sale	35.00	22,500	787,500	15,577	Sep 13 08:24 PM
Adams Brian	General Counsel	Sep 13	Sale	35.02	6,500	227,630	25,577	Sep 13 08:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience